Trials / Completed
CompletedNCT02073838
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Sarit Assouline · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ribavirin | |
| DRUG | Vismodegib | |
| DRUG | Decitabine |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2014-02-27
- Last updated
- 2023-09-29
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02073838. Inclusion in this directory is not an endorsement.